Last mentioned: 19h ago
Monash IVF cuts FY26 profit guidance to $17-18M, citing a 4.7% drop in ART cycles, while fending off a $0.90 takeover bid. The financial story now hinges on cost-cutting, international growth, and the possibility of a renewed offer.
Monash IVF’s profit downgrade and a high-profile embryo mix-up signal deeper turmoil in Australia’s ART market, with biotech and pharma implications for fertility drug and device manufacturers.
A staggering 70% of Australians living with incontinence are not seeking professional medical assistance, highlighting a deep-seated social stigma and a massive gap in the healthcare market. This 'silent epidemic' presents a significant opportunity for digital health interventions and telehealth platforms to bridge the care gap through private, accessible solutions.